TY - JOUR
T1 - Impact of COVID-19 on Pediatric Asthma
T2 - Practice Adjustments and Disease Burden
AU - Papadopoulos, Nikolaos G.
AU - Custovic, Adnan
AU - Deschildre, Antoine
AU - Mathioudakis, Alexander G.
AU - Phipatanakul, Wanda
AU - Wong, Gary
AU - Xepapadaki, Paraskevi
AU - Agache, Ioana
AU - Bacharier, Leonard
AU - Bonini, Matteo
AU - Castro-Rodriguez, Jose A.
AU - Chen, Zhimin
AU - Craig, Timothy
AU - Ducharme, Francine M.
AU - El-Sayed, Zeinab Awad
AU - Feleszko, Wojciech
AU - Fiocchi, Alessandro
AU - Garcia-Marcos, Luis
AU - Gern, James E.
AU - Goh, Anne
AU - Gómez, René Maximiliano
AU - Hamelmann, Eckard H.
AU - Hedlin, Gunilla
AU - Hossny, Elham M.
AU - Jartti, Tuomas
AU - Kalayci, Omer
AU - Kaplan, Alan
AU - Konradsen, Jon
AU - Kuna, Piotr
AU - Lau, Susanne
AU - Le Souef, Peter
AU - Lemanske, Robert F.
AU - Mäkelä, Mika J.
AU - Morais-Almeida, Mário
AU - Murray, Clare
AU - Nagaraju, Karthik
AU - Namazova-Baranova, Leyla
AU - Garcia, Antonio Nieto
AU - Yusuf, Osman M.
AU - Pitrez, Paulo M.C.
AU - Pohunek, Petr
AU - Pozo Beltrán, Cesar Fireth
AU - Roberts, Graham C.
AU - Valiulis, Arunas
AU - Zar, Heather J.
AU - Taam, Rola Abou
AU - Azuara, Hugo
AU - Brouard, Jacques
AU - Cros, Pierrick
AU - De Lira, Cindy
AU - Dubus, Jean Christophe
AU - Dunder, Teija
AU - Efendieva, Kamilla
AU - Egron, Carole
AU - Emeryk, Andrzej
AU - Huerta Villalobos, Yunuen R.
AU - Karen, Nidia
AU - Le Roux, Pascal
AU - Levina, Julia
AU - Medley, Monica
AU - Najaraju, Major
AU - Yeverino, Daniela Rivero
AU - Ruotsalainen, Marja
AU - Szefler, Stanley
AU - Schweitzer, Cyril
AU - Benhumea, Berenice Velasco
AU - Villarreal, Rosalaura
AU - Weiss, Laurence
AU - Zawadzka-Krajewska, Anna
N1 - Funding Information:
This study was supported by the Respiratory Effectiveness Group (REG). REG has received support from AstraZeneca, Novartis, and Sanofi for continued work on Pediatric Asthma in Real Life. A.G.M. was supported by the National Institute of Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC).Conflicts of interests: J. Konradsen reports grants from Region Stockholm, during the conduct of the study. N. G. Papadopoulos reports personal fees from ALK, Novartis, Nutricia, HAL, Menarini/FAES Farma, Sanofi, Mylan/MEDA, Biomay, AstraZeneca, GlaxoSmithKline (GSK), MSD, ASIT BIOTECH, and Boehringer Ingelheim and grants from Gerolymatos International SA and Capricare, outside the submitted work. A. Custovic reports personal fees from Novartis, Regeneron/Sanofi, Thermo Fisher Scientific, Boehringer Ingelheim, and Philips, outside the submitted work. A. Deschildre reports grants and personal fees from Stallergenes Greer and personal fees from Novartis, ALK, Teva, GSK, MEDA-MYLAN, CHIESI, AImmune, DBV Technologies, and Astra Zeneca, outside the submitted work. A. G. Mathioudakis reports grants from Boehringer Ingelheim, outside the submitted work. W. Phipatanakul reports grants from the National Institutes of Health (NIH); grants and personal fees from Genentech/Novartis and Sanofi/Rgeneron; personal fees from GSK; and nonfinancial support from Thermo Fisher, Lincoln Diagnostics, Alk Abello, and Monaghen, outside the submitted work. P. Xepapadaki reports personal fees from Nutricia, Nestle, Friesland, Uriach, Novartis Pharma AG, and GSK, outside the submitted work. L. Bacharier reports personal fees from Aerocrine, GSK, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, and Circassia, outside the submitted work. T. Craig reports grants and personal fees from CSL Behring, Dyax, Takeda, BioCryst, and Pharming; personal fees from Grifols; and grants and nonfinancial support from GSK, Regeneron, and Novartis/Genetech, outside the submitted work. F. M. Ducharme reports grants from Thorasys Inc; personal fees from Jean-Coutu Pharmaceuticals; and nonfinancial support from Novartis Canada, and Trudell Medical, outside the submitted work. J. E. Gern reports grants from NIH/National Institute of Allergy and Infectious Diseases; personal fees from Regeneron, Ena Theraputics, and MedImmune, outside the submitted work; and personal fees and stock options from Meissa Vaccines Inc, outside the submitted work. A. Kaplan reports personal fees from Astra Zeneca, Behring, Boehringer Ingelheim, Covis, GSK, NovoNordisk, Novartis, Griffols, Pfizer, Sanofi, Teva, and Trudel, outside the submitted work. P. Kuna reports personal fees from Adamed, Boehringer Ingelheim, AstraZeneca, Berlin Chemie Menarini, Hal, Lekam, Mylan, Novartis, Polpharma, and Teva, outside the submitted work. R. F. Lemanske reports grants from the NIH, Clinical and Translational Science Award (NIH), Childhood Origins of ASThma, and AsthmaNet; nonfinancial support from GSK, Boehringer Ingelheim, Merck, Teva, and the American Academy of Allergy, Asthma & Immunology; and personal fees from LSU, Elsevier, UpToDate, the University of Kentucky, ThermoFischer, and Food Allergy Research and Education Network, outside the submitted work. C. Murray reports personal fees from Novartis, GSK, Astra Zeneca, Thermo Fisher, and Boehringer Ingelheim, outside the submitted work. P. M. C. Pitrez reports grants from AstraZeneca, Chiesi, and Teva and personal fees from Astra Zeneca, Teva, Novartis, Mundipharma, S&D Pharma, and GSK, outside the submitted work. G. C. Roberts reports personal fees from ALK, Allergen Therapeutics, Meda Plus, and Merck; and a patent for the use of sublingual immunotherapy to prevent the development of allergy in at-risk infants, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
This study was supported by the Respiratory Effectiveness Group (REG). REG has received support from AstraZeneca , Novartis , and Sanofi for continued work on Pediatric Asthma in Real Life. A.G.M. was supported by the National Institute of Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC) .
Publisher Copyright:
© 2020 American Academy of Allergy, Asthma & Immunology
PY - 2020/9
Y1 - 2020/9
N2 - Background: It is unclear whether asthma may affect susceptibility or severity of coronavirus disease 2019 (COVID-19) in children and how pediatric asthma services worldwide have responded to the pandemic. Objective: To describe the impact of the COVID-19 pandemic on pediatric asthma services and on disease burden in their patients. Methods: An online survey was sent to members of the Pediatric Asthma in Real Life think tank and the World Allergy Organization Pediatric Asthma Committee. It included questions on service provision, disease burden, and the clinical course of confirmed cases of COVID-19 infection among children with asthma. Results: Ninety-one respondents, caring for an estimated population of more than 133,000 children with asthma, completed the survey. COVID-19 significantly impacted pediatric asthma services: 39% ceased physical appointments, 47% stopped accepting new patients, and 75% limited patients' visits. Consultations were almost halved to a median of 20 (interquartile range, 10-25) patients per week. Virtual clinics and helplines were launched in most centers. Better than expected disease control was reported in 20% (10%-40%) of patients, whereas control was negatively affected in only 10% (7.5%-12.5%). Adherence also appeared to increase. Only 15 confirmed cases of COVID-19 were reported among the population; the estimated incidence is not apparently different from the reports of general pediatric cohorts. Conclusions: Children with asthma do not appear to be disproportionately affected by COVID-19. Outcomes may even have improved, possibly through increased adherence and/or reduced exposures. Clinical services have rapidly responded to the pandemic by limiting and replacing physical appointments with virtual encounters.
AB - Background: It is unclear whether asthma may affect susceptibility or severity of coronavirus disease 2019 (COVID-19) in children and how pediatric asthma services worldwide have responded to the pandemic. Objective: To describe the impact of the COVID-19 pandemic on pediatric asthma services and on disease burden in their patients. Methods: An online survey was sent to members of the Pediatric Asthma in Real Life think tank and the World Allergy Organization Pediatric Asthma Committee. It included questions on service provision, disease burden, and the clinical course of confirmed cases of COVID-19 infection among children with asthma. Results: Ninety-one respondents, caring for an estimated population of more than 133,000 children with asthma, completed the survey. COVID-19 significantly impacted pediatric asthma services: 39% ceased physical appointments, 47% stopped accepting new patients, and 75% limited patients' visits. Consultations were almost halved to a median of 20 (interquartile range, 10-25) patients per week. Virtual clinics and helplines were launched in most centers. Better than expected disease control was reported in 20% (10%-40%) of patients, whereas control was negatively affected in only 10% (7.5%-12.5%). Adherence also appeared to increase. Only 15 confirmed cases of COVID-19 were reported among the population; the estimated incidence is not apparently different from the reports of general pediatric cohorts. Conclusions: Children with asthma do not appear to be disproportionately affected by COVID-19. Outcomes may even have improved, possibly through increased adherence and/or reduced exposures. Clinical services have rapidly responded to the pandemic by limiting and replacing physical appointments with virtual encounters.
UR - http://www.scopus.com/inward/record.url?scp=85086785534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086785534&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.06.001
DO - 10.1016/j.jaip.2020.06.001
M3 - Article
C2 - 32561497
AN - SCOPUS:85086785534
SN - 2213-2198
VL - 8
SP - 2592-2599.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 8
ER -